TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options Under Clinical Evaluation for Childhood and AYA Breast Cancer
Source: Childhood Breast Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: September 11, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Source links and citations
The following is an example of a national and/or institutional clinical trial that is currently being conducted:
NCT05879926 (Testing the Addition of Chemotherapy to the Usual Treatment of Ovarian Function Suppression Plus Hormonal Therapy in Premenopausal Estrogen Receptor (ER)–Positive/HER2-Negative Breast Cancer Patients Who Are At High Risk of Cancer Returning [OFSET Trial]): This phase III trial will determine whether adjuvant chemotherapy added to ovarian function suppression and endocrine therapy improves invasive breast cancer–free survival among premenopausal, early-stage breast cancer patients (aged 18 years and older) with ER-positive, HER2-negative tumors and a 21-gene recurrence score between 16 and 25 (for pN0 patients) or 0 and 25 (for pN1 patients).
Source links and citations
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Preserved source evidence · Not medical advice